Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Intervacc AB is a prominent pharmaceutical company focused on developing and commercializing innovative vaccines within the veterinary sector. The primary aim of Intervacc AB is to enhance animal health by providing effective preventive treatments against infectious diseases in livestock and pets. The company's notable venture includes creating vaccines that address major concerns in veterinary medicine, significantly impacting sectors such as agriculture, dairy, and companion animal care. Intervacc AB's products are crucial in ensuring healthier livestock that contribute to more stable and secure food supplies worldwide. Founded with a commitment to scientific excellence and animal welfare, Intervacc AB stands out for its dedication to research and collaborations with academic and industry partners. In the financial market, the firm represents a growing interest in biotechnology solutions for animal health, with potential implications for public health and food safety. Based in Sweden, Intervacc AB plays a key role in integrating biotechnological advancements into practical veterinary applications, aiming to reduce the reliance on antibiotics and promote sustainable animal farming practices.
kr 0.07
kr 0.00 (-2.57%)
Live · 08:36 PM · Twelve Data
The business is unprofitable at the operating level (-415.70% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 70.4% YoY with margins expanding 239.9pp.
Negative free cash flow of -kr 67M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 19M
▲ +70.4% YoY
Net Income (TTM)
-kr 89M
▼ -7.0% YoY
Op. Margin
-488.12%
▲ +239.9pp YoY
ROIC
-30.16%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 71M
▼ -24.1% YoY
Op. Cash Flow (TTM)
-kr 26M
▼ -22.0% YoY
Net Debt
-kr 161M
Net Cash Position
Cash & Equiv.
kr 161M
3Y CAGR: +27.5%
Continue Research
Intervacc AB (IVACC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Intervacc AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Intervacc AB scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -488.1% operating margin and a -30.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh IVACC.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.